Little evidence exists to guide risk stratification and management of patients with prior coronary artery stenting who require noncardiac surgery. While clinical models for perioperative risk stratification have been established, few studies have examined angiographic contributors to perioperative risk. Methods: We examined 405 patients with prior coronary artery stenting who underwent non-cardiac surgery between 8/23/2001 and 12/27/2009 at a tertiary care institution for whom detailed information on coronary anatomy and perioperative treatment could be obtained. Coronary angiograms were independently reviewed, and patients were followed for a median of 3.1 years after surgery. Results: In our study population, 52% had prior MI, 18% had prior stroke/TIA, and 26% had prior heart failure. The median time from PCI to surgery was 325 days (interquartile range [IQR] 81 to 808). Among these patients, 35% were stented electively, 14% were stented in the STEMI setting, and 51% were stented in the NSTE ACS setting. Lesions treated included 18 previously stented lesions, 83 bifurcation lesions, 117 highly calcified lesions, and 53 lesions with visible thrombus. A total of 188 patients (46%) were treated with Ն1 stent, with a median stent diameter of 3mm (IQR 2.5-3) and a median stent length of 18 mm (IQR 13 to 23). A total of 243 patients (60%) were stented with Ն1 drug eluting stent (DES). At the time of surgery, 125/220 (57%) patients still on clopidogrel stopped clopidogrel at a median of 8 days (IQR 5-11) prior to surgery. Among 116 DES patients undergoing surgery within a year of stent implantation, 37 (32%) stopped clopidogrel prior to surgery, and 12 (10%) were bridged with a parenteral antithrombotic agent. Perioperative MI occurred in 19 patients (4.7%). Perioperative bleeding defined as a preoperative to nadir hematocrit difference Ն10% occurred in 114 patients (28%) and transfusions were given in 65 patients (16%). The 3-year mortality risk was 17%. Conclusions: Patients with coronary disease undergoing noncardiac surgery remain a high risk population for whom evidence-based strategies are greatly needed to improve perioperative outcomes.
TCT-562 Temporal Trends In Cost and Resource Utilization Following PCI-Associated Gastrointestinal Bleeding
Background: Gastrointestinal bleeding (GIB) remains a serious complication for patients undergoing percutaneous coronary intervention (PCI). Little is known about the resource utilization and cost for patients with GI bleeding following PCI. We sought to analyze healthcare resource utilization, cost, and mortality during the study period from 1998-2006 for patients with post-PCI GI bleed. Methods: The Nationwide Inpatient Sample (NIS), which contains over a hundred clinical and nonclinical data elements, was analyzed from 1998 to 2006. The primary analysis was to assess the added hospitalization cost for PCI associated GIB over the study period. The secondary analysis looked at resource utilization of PCI associated GIB. GIB was defined as any active bleeding from the upper or lower GI tract. Multivariate linear regression model was used to adjust for baseline procedure variables. All tests were 2-tailed, with pϽ0.05 considered significant. Results: There were 1,204.065 patients without GIB and 12,694 (1.04%) with post-PCI GIB. Post-PCI GIB was associated with increased average hospital cost ($60,094 vs. $36,758, pϽ0.001) over the study period and increased mortality (6.0% vs. 0.76%, pϽ0.001) when compared to PCI without GIB. The overall cost increased for both groups during the study period (p for trendϽ0.001) due to increasing cost of PCI (pϽ0.0001). The added cost for patients that suffered GIB ($23,336) was secondary to increased need for blood product administration; FFP ($10,045) and PRBC ($4110), both pϽ0.0001), and pulmonary artery catheterization ($ 8,612) (pϽ0.0001). Upper and lower endoscopy did not significantly add to cost for patients with GIB (pϭ0.91).
Conclusions:
The overall cost of PCI increased over the study period. PCI-associated GIB is associated with higher mortality. Incremental costs of GIB are due to blood product administration and expense associated with hemodynamic monitoring.
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